TABLE 3.
SVR12 rate of the major HCV genotypes stratified by DAA regimens, treatment experience and cirrhotic status
| n/N (%) | All | G1 | G2 | G3 | G6 | Unclassified |
|---|---|---|---|---|---|---|
| SOF + RBV | 1609/1670 (96.4) | 5/5 (100.0) | 1596/1657 (96.3) | 2/2 (100.0) | – | 6/6 (100.0) |
| Naïve non‐LC | 689/706 (97.6) | 1/1 (100.0) | 686/703 (97.6) | – | – | 2/2 (100.0) |
| Naïve LC | 724/752 (96.3) | 3/3 (100.0) | 718/746 (99.2) | – | 3/3 (100.0) | |
| Exp. non‐LC | 83/85 (97.7) | ‐ | 82/84 (97.6) | 1/1 (100.0) | – | |
| Exp. LC | 113/127 (89.0) | 1/1 (100.0) | 110/124 (88.7) | 1/1 (100.0) | – | 1/1 (100.0) |
| DCV/ASV | 532/556 (95.7) | 531/555 (95.7) | – | – | – | 1/1 (100.0) |
| Naïve non‐LC | 110/116(94.8) | 110/116 (94.8) | – | – | – | – |
| Naïve LC | 139/142(97.9) | 139/142 (97.9) | – | – | – | – |
| Exp. non‐LC | 119/125 (95.2) | 118/124 (95.2) | – | – | – | 1/1 (100.0) |
| Exp. LC | 164/173(94.8) | 164/173 (94.8) | – | – | – | – |
| PrOD + RBV | 2493/2524 (98.8) | 2493/2524 (98.8) | – | – | – | – |
| Naïve non‐LC | 520/525 (99.1) | 520/525 (99.1) | – | – | – | – |
| Naïve LC | 613/621 (98.7) | 613/621 (98.7) | – | – | – | – |
| Exp. non‐LC | 513/521 (98.5) | 513/521 (98.5) | – | – | – | – |
| Exp. LC | 847/857 (98.8) | 847/857 (98.8) | – | – | – | – |
| EBR/GZR | 2070/2099 (98.6) | 2064/2090 (98.8) | 1/1 (100.0) | – | 2/2 (100.0) | |
| Naïve non‐LC | 1256/1268 (99.1) | 1253/1264 (99.1) | 1/1 (100.0) | – | 1/1 (100.0) | |
| Naïve LC | 562/574 (97.9) | 561/572 (98.1) | – | – | – | – |
| Exp. non‐LC | 132/135 (97.8) | 131/134 (97.8) | – | – | – | 1/1 (100.0) |
| Exp. LC | 120/122 (98.4) | 119/120 (99.2) | – | – | – | – |
| SOF + DCV ± RBV | 518/523 (99.0) | 22/22 (100.0) | 481/485 (99.2) | 2/2 (100.0) | 1/2 (50.0) | 5/5 (100.0) |
| Naïve non‐LC | 196/198 (99.0) | 7/7 (100.0) | 183/184 (99.5) | 2/2 (100.0) | 1/2 (50.0) | |
| Naïve LC | 229/231 (99.1) | 8/8 (100.0) | 213/215 (99.1) | – | – | 5/5 (100.0) |
| Exp. non‐LC | 42/42 (100.0) | 6/6 (100.0) | 35/35 (100.0) | – | – | |
| Exp. LC | 51/52(98.1) | 1/1 (100.0) | 50/51 (98.0) | – | – | |
| SOF/LDV ± RBV | 4040/4101 (98.5) | 2075/2104 (98.6) | 1472/1497 (98.3) | – | 412/417 (98.8) | 28/28 (100.0) |
| Naïve non‐LC | 2569/2606 (98.6) | 1037/1049 (98.9) | 1225/1245 (98.4) | – | 259/262 (98.9) | 17/17 (100.0) |
| Naïve LC | 1023/1043 (98.1) | 713/727 (98.1) | 174/178 (97.8) | – | 114/116 (98.3) | 2/2 (100.0) |
| Exp. non‐LC | 257/258 (99.6) | 174/174 (100.0) | 55/56 (98.2) | – | 21/21 (100.0) | 5/5 (100.0) |
| Exp. LC | 191/194 (98.5) | 151/154 (98.1) | 18/18 (100.0) | – | 18/18 (100.0) | 4/4 (100.0) |
| SOF/VEL | 405/410 (98.8) | 169/171 (98.8) | 204/206 (99.0) | 9/10 (90.0) | 14/14 (100.0) | 1/1 (100.0) |
| Naïve non‐LC | 241/241 (100.0) | 103/103 (100.0) | 119/119 (100.0) | 5/5 (100.0) | 10/10 (100.0) | 1/1 (100.0) |
| Naïve LC | 96/97 (99.0) | 33/33 (100.0) | 51/51 (100.0) | 3/4 (75.0) | 4/4(100.0) | – |
| Exp. non‐LC | 40/42 (95.2) | 21/21 (100.0) | 19/21 (90.5) | – | 0/0 (0.0) | – |
| Exp. LC | 28/30 (93.3) | 12/14 (85.7) | 15/15(100.0) | 1/1 (100.0) | 0/0 (0.0) | – |
| GLE/PIB | 1969/1989 (99.0) | 567/567 (100.0) | 1143/1158 (98.7) | 82/86 (95.4) | 107/108 (99.1) | 23/23 (100.0) |
| Naïve non‐LC | 1491/1507 (98.9) | 421/421 (100.0) | 882/895 (98.6) | 61/64 (95.3) | 77/77 (100.0) | 19/19 (100.0) |
| Naïve LC | 276/279 (98.9) | 55/55 (100.0) | 183/184 (99.5) | 10/11 (90.9) | 15/16 (93.8) | 3/3 (100.0) |
| Exp. non‐LC | 144/144 (100.0) | 73/73 (100.0) | 52/52 (100.0) | 4/4 (100.0) | 12/12 (100.0) | 1/1 (100.0) |
| Exp. LC | 58/59 (98.3) | 18/18 (100.0) | 26/27 (96.3) | 7/7 (100.0) | 3/3 (100.0) | – |
Abbreviations: ASV, asunaprevir; DCV, daclatasvir; EBR, elbasvir; Exp, experienced; G1, genotype 1; GLE, glecaprevir; GZR, grazoprevir; LC, liver cirrhosis; LDV, ledipasvir; PIB, pibrentasvir; PrOD, paritaprevir/ritonavir/ombitasvir/dasabuvir; RBV, ribavirin; SOF, sofosbuvir; SVR, sustained virological response; VEL, velpatasvir; VOX, voxilaprevir.